14 firms get license to evaluate COVID-19 tests kits

Image
Press Trust of India New Delhi
Last Updated : Mar 20 2020 | 6:20 PM IST

Fourteen private companies including Swiss firm Roche Diagnostics Indiahave been given test license by the drug regulator DCGI for evaluation of the quality of COVID-19 testing kits, a CDSCO officialsaid.

Apart from Roche Diagnostics India, rest of the 13 are Indian firms includeCoSara Diagnostics from Ahmedabad and CPC Diagnostics from Chennai.

All thesecompanies will evaluate the quality of testing kits and submit their data to the Drug Controller General of India.

Roche Diagnostics India received the license from the country's drug regulator DCGI for its 'cobas SARS CoV-2' diagnostic test kit on March 17.

"We are now assessing giving license to another private diagnostic firm, bioMrieux, which has also sought approval besides three other companies," the official from Central Drugs Standard Control Organisation said.

The development comes after the Indian Council of Medical Research (ICMR) announced that accredited private labs will conduct tests for COVID-19 to enhance capacity for diagnosis and detection of novel coronavirus amid rising cases in the country.

The Union Health ministry had on Tuesday issued guidelines for private sector laboratories intending to initiate COVID-19 testing while the ICMR appealed them to conduct the tests free of cost.

Laboratory tests for coronavirus at private labs should be offered when prescribed by a qualified physician as per the ICMR guidelinesfor testing.

"Private labs testing is to ensure real time reporting to the Integrated Disease Surveillance Programme (IDSP) and the ICMR headquarters for timely initiation of contact tracing and research activities," the ministry said.

ICMR will share the standard operating procedure for laboratory testing and provide positive controls for establishing the test as soon as the private laboratory concerned has procured the primers, probes and reagents.

Adoption of commercial kits for testing should be based on validations conducted by the ICMR and National Institute of Virology (NIV) in Pune.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 20 2020 | 6:20 PM IST

Next Story